1. Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
- Author
-
Einsley-Marie eJanowski, Leonard N Chen, Joy S Kim, Thomas M Yung, Brian Timothy Collins, Simeng eSuy, John J Lynch, Anatoly eDritschilo, and Sean P Collins
- Subjects
Dysuria ,prostate cancer ,CyberKnife ,SBRT ,stereotactic body radiation therapy ,quality of life. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. Methods: 204 patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow up of three years were included in this retrospective review of prospectively collected data. All patients were treated to 35-36.25Gy in 5 fractions delivered with robotic SBRT with real time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via Question 4b (Pain or burning on urination) of the Expanded Prostate Index Composite (EPIC)-26 and the American Urological Association (AUA) Symptom Score at baseline and at routine follow up. Results: 204 patients (82 low-, 105 intermediate-, and 17 high risk according to the D’Amico classification) at a median age of 69 years (range 48-91) received SBRT for their localized prostate cancer with a median follow up of 47 months. Bother associated with dysuria significantly increased from a baseline of 12% to a maximum of 43% at one month (p
- Published
- 2015
- Full Text
- View/download PDF